Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
International Conference on Cancer Research: New Horizons 19th-21st November, 2015, Venue: National Centre for Cell Science, Pune, INDIA Programme Schedule Day 1: 19th November, 2015 08.30 am-9.30 am Registration 9.30 am-10.00 am Inauguration Session-I: Cancer Epigenetics & Therapy Chairs: Dr. D. Mitra & Dr. S. A. Bapat 10.00-10.20 am I-1: Integration of Epigenetic and Hormone Signaling in Prostate Cancer Prof. Debabrata Chakravarthi, Northwestern University, USA 10.20-10.40 am I-2: NPM1 Mediated Induction of p300 Autoacetylation and RNA Pol II Driven Transcription: Implications in Oral Cancer Prof. Tapas Kundu, JNCASR, India 10.40-11.00 am: Tea Break 11.00-11.20 am I-3: Exploring DNA Double-strand Break Repair for its Role in Chromosomal Translocations and its Use as a Cancer Therapeutic Target Dr. Sathees Raghavan, IISc, India 11.20-11.40 am I-4: Cross-talk between ubiquitylation and phosphorylation mediate the turnover and mitotic functions of BLM helicase Dr. Sagar Sengupta, NII, India 11.40-11.55am S-1: Protein phosphatase 1 regulatory subunit p90 suppresses tumor growth through inactivation of MAPK pathway and is epigenetically silenced in feedback loop Mr. Debashish Paul, NCCS, India 1 Session-II:Cancer Immunobiology & Therapy Chairs: Dr. G. C. Mishra & Dr. G. Lal 11.55-12.15 pm I-5: Contribution of MDSC and Tregs to immune suppressive network in oral cancer Dr. Shubhada Chiplunkar, ACTREC, India 12.15-12.35 pm I-6: Intratumoral immune landscape: From immunogenicity to tolerogenicity Prof. Gaurishankar Sa, Bose Institute, India 12.35-12.55 pm I-7: Polypyrimidine tract binding protein 2 is upregulated during CML disease progression and its deregulation in CML cells efficiently blocks cell cycle, cell proliferation and promotes apoptosis Dr. Soumen Chakraborty, ILS, India 12.55-1.10 pm S-2: Intratumoral natural killer (NK) cells inhibit the differentiation of effector Th1 cells and promote tumor growth Mr. Sourav Paul, NCCS, India 1.10-2.10 pm Lunch Break Session-III: Mechanism of Tumor Progression & Drug Resistance Chairs:Dr. Padma Shastry & Dr. M. K. Bhat 2.10-2.30 pm I-8: ABC drug transporters and cancer chemotherapy Dr. Suresh Ambudkar, NCI, USA 2.30-2.50 pm I-9: Tryptanthrin: A potent anti-melanoma molecule from Wrightia tinctoria Dr. Ruby Anto, RGCB, India 2.50-3.05 pm S-3: Metal based Ayurvedic Nano compounds in cancer therapy: An Unexplored goldmine for research Dr. Yogesh Bendale,Rasayu Cancer Clinic, India 3.05-3.20 pm S-4: AMPK mediated metabolic orchestration and mitochondrial biogenesis is decisive for cancer cell survival under metabolic stress Mr. Balkrishna Chaube, NCCS, India 2 3.20-4.50 pm Tea Break & Poster Presentation (Poster No. P01 to P30) Session-IV: Stem Cell & Cancer Chairs: Dr. L. Limaye & Dr. Anjali Shiras 04.50-5.10 pm I-10: Cancer stem cells and chemo-resistance: An approach towards targeting ‘cellular plasticity’ in breast tumor Prof. Tanya Das, Bose Institute,India 5.10-5.30 pm I-11: Cancer Stem Cells: Link between anchorage-independent growth and drug resistance Dr. Annapoorni Rangarajan, IISc, India 5.30-5.45 pm S-5: Notch1-MAPK Signaling Axis Regulates CD133+ Melanoma Initiating Cell Growth and Metastasis Mr. Dhiraj Kumar, NCCS, India 5.45-6.00 pm S-6: A Tumor Deconstruction Platform Identifies Definitive End Points in the Evaluation of Drug Responses Ms. Rutika Naik, NCCS, India 6.15-8.00 pm Cultural Programme 8.00-10.00 pm Day-2: Dinner at NCCS Amphitheater 20th November, 2015 Session-V: Clinical Cancer Research: Therapy and Biomarker Chairs: Dr. G.C. Kundu & Dr. Srikanth Rapole 9.30-9.50 am I-12: Precision and Personalized Medicine for Breast Cancer: Challenges and Opportunities Dr. Sudeep Gupta, TMH & ACTREC, India 9.50-10.10 am I-13: "Prognostic markers in breast cancer: is there light at the end of the tunnel" Dr. Diptendra Sarkar, IPGME&R and SSKM Hospital, India 3 10.10-10.30 am I-14: Targetable Alterations in Gynecologic Malignancies – Present and Future Dr. Shona Nag, Jehangir Hospital, India 10.30-10.50 am I-15: Molecular markers in breast cancer and their clinical relevance Dr. Anupama Mane, Ruby Hall Clinic, India 10.50-11.10 am Tea Break 11.10-11.30 am I-16: Clinical Practice in Breast Cancer: Lessons from Molecular Biology Dr. C. B. Koppiker, Orchids Breast Health Center, India 11.30-11.45 am S-7: Identification of potential biomarkers in breast cancer using complementary gel-based and gel-free quantitative proteomic approaches Ms. Akshada Gajbhiye, NCCS, India 11:45-12:45 pm Session- VI: Panel Discussion: Status of Basic and Clinical Cancer Research in India and around the Globe: Where do we stand? Moderators: Dr. G. C. Kundu & Dr. S. A. Bapat Panelists: Dr. Shubhada Chiplunkar, Dr. Sudeep Gupta, Dr. Deirdre Coombe, Dr. M. K. Bhat, Dr. A. Shiras, Dr. Diptendra Sarkar, Dr. Shona Nag, Dr. Anupama Mane, Dr. C. B. Koppikar, Prof. Debabrata Chakravarti, Prof. Tapas Kundu 12.45-1.45 pm Lunch Break Session-VII: Cancer Drug Development Chairs: Dr. M. R. Wani & Dr. V. P. Kale 1.45-2.05 pm I-17: The linkage between microtubule dynamics, apoptosis and drug resistance Prof. Dulal Panda, IITB, India 4 2.05-2.25 pm I-18: Transcriptional deregulation and spatial organization of aneuploid chromosomes in cancer cells Dr. Kundan Sengupta, IISER, India 2.25-2.45 pm I-19: Identification of altered cellular pathways associated with the development of uterine cervical carcinoma in Indian patients Dr. Chinmay Kumar Panda, CNCI, India 2.45-3.05 pm 3.05-3.20 pm I-20: Targeting P21 activated kinase 1 (Pak1) to PAKup Pancreatic Cancer Dr. Suresh Rayala, IITM, India S-8: Reassembling glioblastoma in a dish: From personalized therapy to drug discovery Mr. Aman Sharma, NCCS, India 3.20-4.50 pm Tea Break and Poster Presentation (Poster No. 31-60) Session-VIII: Targeted Therapy in Cancer: Genetic, Epigenetic & Chemical Biology Approach Chairs: Prof. J. K. Pal & Dr. Manas Santra 4.50-5.10 pm I-21: Melanoma Cell Adhesion Molecule (MCAM/CD146): Endocytosis, cell migration and tumour formation Prof. Deirdre Coombe, Curtin University, Australia 5.10-5.30 pm I-22: Chromatin organizer SATB1 as molecular target for cancer therapy: a novel mechanism for anti-cancer activity of Statins Prof. Sanjeev Galande, IISER, India 5.30-5.50 pm I-23: An update on PSP94: Structure, Function and application in prostate cancer diagnosis Dr. Smita Mahale, NIRRH, India 5.50-6.10 pm I-24: Loss of 14-3-3 leads to the induction of an Epithelial Mesenchymal Transition Dr. Sorab Dalal, ACTREC, India 5 6.10-6.30 pm I-25: Genome-wide analysis of squamous cell carcinoma of the oral tongue reveals novel insights into wild type and mutant TP53 transcription program Dr. Murali Bashyam, CDFD, India 6.30-6.50 pm I-26: Integrated Genomics Approach to Identify Biologically Relevant Alterations in Fewer Samples Dr. Amit Dutt, ACTREC, India 7.00- 7.45 pm: Transport to Le Royale Hotel 7.45-10.30 pm Banquette Dinner at Le Royale Hotel Day 3: 21st November, 2015 Session-IX: Tumor Suppressor, Regulation of Gene Expression & Therapeutic Target in Cancer Chairs: Dr. J. Joseph & Dr. Deepa Subramanyam 9.00-9.20 am I-27: Regulation of tumor suppressor gene SMAR1 in cancers Dr. Samit Chattopadhyay, IICB, India 9.20-9.40 am I-28: Signaling Crosstalk and Gene Regulation in Cancer to Identify Novel Target(s) for Therapeutics Dr. Mrinal Ghosh, IICB, India 9.40-9.55am S-9: Evaluation of agents of diverse origin for their anticancer activity in vitro Dr. Kalpana Pai, SPP University, India 9.55-10.10 am S-10: Putting Cancer Cells to Sleep: A Novel Safer Approach for Intervention Dr. Gunjan Guha, SASTRA University, India 6 10.10-10.25 am S-11: Evaluation of cinnamaldehyde functionalized magnetite nanoparticles for hyperthermia and drug delivery applications in breast cancer Dr. Ruchika Kaul-Ghanekar, IRSHA, India 10.25-10.40 am S-12: p53 causes histone deacetylation to downregulate Pro-Metastasis Proteins Toca-1 and FBP17 in Breast Cancer Dr. Harish Chander, Central University of Punjab, India 10.40-10.55 am S-13: Dietary flavonoids for the reversal of P-glycoprotein mediated Multi-drug resistance Dr. Rajendra Prasad, Annamalai University, India 10.55-11.10 am S-14: iNOs+ macrophages represent Potential Alternate of Radiotherapy for the Treatment of Pancreatic tumors Dr. Hridayesh Prakash, University of Hyderabad, India 11.10-11.30 am Tea Break Session X: Nanomedicine in Cancer & Cancer Metabolism Chairs: Dr. D. K. Tewary & Prof. Ameeta Ravi Kumar 11.30-11.50 am I-29: Protective metabolic cross-talk between tumour and stroma in acute lymphoblastic leukaemia Dr. Vaskar Saha, TMC, India 11.50-12.10 pm I-30: Implantable nanomedicines: A short-cut to bypass systemic toxicity and biological barriers Dr. Manzoor K, Amrita University, India 12.10-12.30 pm I-31: Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells Dr. Sudipta Basu, IISER, India 12.30-12.50 pm I-32: Eco-fabrication of biomedically and technologically important nanoparticles Dr. Absar Ahmad, NCL, India 7 12.50-1.10 pm I-33: Nanomedicines: Vehicle for Targeted Drug Delivery Prof. Suresh Gosavi, SPP University, India 1.10-1.40 pm Session XI: Valedictory, Poster Award & Concluding remarks (Dr. S C Mande, Dr. Samit Chattopadhyay, Dr. G C Kundu & Dr. S A Bapat) Vote of thanks Dr. Jyoti Rao 1.40-2.40 pm Lunch 8